Last reviewed · How we verify
Asthma Reliever Therapies
Asthma Reliever Therapies is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Asthma symptom relief.
Asthma Reliever Therapies from Sanofi work to rapidly open airways and reduce airway constriction in asthma patients.
Asthma Reliever Therapies from Sanofi work to rapidly open airways and reduce airway constriction in asthma patients. Used for Asthma symptom relief.
At a glance
| Generic name | Asthma Reliever Therapies |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
This is a broad therapeutic category rather than a single drug entity. Sanofi's asthma reliever therapies in Phase 3 likely include bronchodilators or other agents designed to provide rapid symptom relief during asthma attacks. The specific mechanism depends on the individual compound within this program, which may target beta-2 adrenergic receptors, muscarinic receptors, or other pathways involved in airway smooth muscle relaxation.
Approved indications
- Asthma symptom relief
Common side effects
- Tremor
- Tachycardia
- Headache
- Nervousness
Key clinical trials
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- Improving the Quality of Care for Asthma Patients at Risk of Exacerbations (NA)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- SMART-School-based Asthma Therapy (NA)
- CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma (PHASE4)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asthma Reliever Therapies CI brief — competitive landscape report
- Asthma Reliever Therapies updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Asthma Reliever Therapies
What is Asthma Reliever Therapies?
How does Asthma Reliever Therapies work?
What is Asthma Reliever Therapies used for?
Who makes Asthma Reliever Therapies?
What development phase is Asthma Reliever Therapies in?
What are the side effects of Asthma Reliever Therapies?
Related
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Asthma symptom relief
- Compare: Asthma Reliever Therapies vs similar drugs
- Pricing: Asthma Reliever Therapies cost, discount & access